FDA's Peptide Review: What It Could Mean for Payment Processing
- Thomas Troyer
- 13 hours ago
- 3 min read
The payment processing industry is closely watching the FDA's July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting. Forbes also has a great article on this as well. While much of the discussion centers around healthcare and pharmaceutical regulation, the outcome could have significant implications for payment processing companies, acquiring banks, and merchants operating in the peptide space.
For years, peptide businesses have faced inconsistent treatment from payment processors due to regulatory uncertainty. As the FDA evaluates several widely discussed peptides, the industry may be taking an important step toward greater clarity.
The Seven Peptides Under Review
The FDA committee is evaluating:
BPC-157
KPV
TB-500
MOTS-c
Emideltide (DSIP)
Semax
Epitalon
The committee is considering whether these peptides should eventually be added to the FDA's 503A Bulk Drug Substances List, allowing licensed compounding pharmacies to prepare them pursuant to valid prescriptions if the FDA later completes the required rulemaking process. It's important to understand that this meeting alone does not make these peptides legal for compounding or change existing regulations overnight.
Why Payment Processors Are Paying Attention
One of the biggest challenges facing peptide companies today isn't finding customers—it's finding reliable payment processing.
Many businesses within this industry experience:
Merchant account denials
Higher processing rates
Reserve requirements
Frequent underwriting reviews
Account closures
Limited banking relationships
Much of this stems from regulatory uncertainty rather than poor business practices.
Banks and processors are responsible for managing risk. When an industry lacks clear regulatory guidance, many financial institutions classify it as higher risk.
Could This Change the Industry?
If some of these peptides eventually receive FDA recognition through the appropriate regulatory process, it could gradually improve confidence throughout the payments ecosystem.
Potential long-term benefits include:
More acquiring banks entering the market
Increased competition among processors
Improved underwriting consistency
Lower perceived compliance risk
Better long-term merchant account stability
More payment options for compliant businesses
While no immediate changes should be expected, regulatory clarity often influences how banks and processors evaluate merchant applications over time.
Compliance Will Still Be Critical
Regardless of the FDA's recommendations, payment processors will continue evaluating merchants based on overall business risk.
That includes reviewing:
Website compliance
Product descriptions
Marketing claims
Business transparency
Chargeback history
Customer service practices
Refund policies
Banking history
Corporate documentation
Simply selling a product that receives favorable regulatory attention does not automatically guarantee merchant account approval.
Strong compliance remains one of the biggest factors in obtaining stable payment processing.
What Businesses Should Do Now
Companies operating in the peptide industry should use this time to prepare.
Consider:
Reviewing website compliance
Removing unsupported medical claims
Updating Terms & Conditions and Privacy Policies
Ensuring product descriptions are accurate and transparent
Improving customer communication
Implementing chargeback prevention tools
Keeping business documentation current
These steps can significantly improve underwriting outcomes regardless of future FDA decisions.
How 2nd Amendment Processing Helps
At 2nd Amendment Processing, we understand that businesses operating in emerging or highly scrutinized industries require more than just a merchant account—they need a payment partner who understands the regulatory landscape.
We work closely with acquiring banks and underwriting teams to help merchants present compliant, well-documented applications that maximize their approval opportunities.
Whether regulations tighten or become more favorable, our goal remains the same:
Helping businesses secure reliable payment processing while building long-term banking relationships.
Looking Ahead
The FDA's July 2026 meeting represents an important milestone for the peptide industry, but it is only one step in a broader regulatory process. Even if the committee recommends adding some or all of these peptides to the 503A Bulks List, the FDA must still complete formal rulemaking before any regulatory changes take effect.
For payment processors, banks, and merchants alike, one thing is clear: regulatory clarity often leads to greater market stability. Businesses that prioritize compliance, transparency, and responsible operations will be best positioned to benefit as the industry evolves.
Comments